Low‐dose apatinib and tegafur‐gimeracil‐oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series
A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials. We retrospectively analysed the effect and safety of low-dose apatinib and tegafur-gimeracil-oteracil (TGO) in the treatment of these patients. Six patients treated with low-dose apatinib and TGO showed a disease control rate of 83.3% and grade 1-2 adverse events (AEs). This case series indicates that low-dose apatinib and TGO could be considered as palliative therapy for RCC patients with poor PS.
